OrthoPediatrics (NSDQ:KIDS) this week posted third-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates.
The Warsaw, Indiana-based orthopedics company reported losses of -$2.2 million, or -11¢ per share, on sales of $25.1 million for the three months ended Sept. 30, for a sales growth of 12.94% compared with Q3 2020.
Adjusted to exclude one-time items, earnings per share were -15¢, 13¢ ahead of The Street, where analysts were looking for sales of $26.28 million.
“We are proud to report double-digit growth despite the temporary impact of COVID, RSV, and hospital staffing shortages. International growth was particularly strong indicating continued recovery of these markets. We continue to make substantive progress in advancing our key strategic initiatives, including securing enabling technologies and sponsoring multiple key clinical education events,” president and CEO David Bailey said in a news release.
OrthoPediatrics reiterated its full-year guidance of $97 million to $101 million in revenue.
Shares in KIDS were up 0.54% to $71.91 apiece at market open.